<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>References cited in the European Medicinal Agencies statement (June 10, 2020)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Study</th>
    <th>Aims</th>
    <th>Population</th>
    <th>Conclusion</th>
    <th>Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1. Bean D, et al. doi: 10.13140/RG.2.2.34883.14889/1.</td>
    <td>Exploration of whether ACEi increase the risk of severe COVID-19 infection.</td>
    <td>Inpatients with COVID-19 (
     <italic>n</italic> = 205).
    </td>
    <td>No evidence for ACEi increasing severity of COVID-19. Possible trend towards beneficial effect need to be explored.</td>
    <td>
     <p>Preprint</p>
     <p>Small sample size</p>
    </td>
   </tr>
   <tr>
    <td>2. de Abajo F, et al. doi: 10.1016/S0140-6736(20)31030-8.</td>
    <td>Epidemiological exploration of possibility that RAASi predispose to severe COVID-19.</td>
    <td>1139 hospitalized cases with COVID-19 and 11,390 controls.</td>
    <td>RAASi do not increase risk of COVID-19 requiring hospital admission. This finding should be confirmed.</td>
    <td>No information on in-hospital RAASi treatment.</td>
   </tr>
   <tr>
    <td>3. Felice C, et al. doi: 10.1093/ajh/hpaa096.</td>
    <td>Association between chronic use of ACEi or ARB and COVID-19 outcomes in hypertensives.</td>
    <td>133 COVID-19 hypertensives admitted with acute respiratory symptoms and/or fever.</td>
    <td>RAASi do not negatively affect clinical course of COVID-19 in hypertensives. Finding should be confirmed.</td>
    <td>Small sample size</td>
   </tr>
   <tr>
    <td>4. Gao C, et al. doi: 10.1093/eurheartj/ehaa433.</td>
    <td>Association between treatment of hypertension and mortality of patients with COVID-19.</td>
    <td>2877 hospitalized COVID-19 patients.</td>
    <td>No harm of RAASi in patients infected with COVID-19. Results should be considered as exploratory and interpreted cautiously.</td>
    <td>Remaining questions: (i) which medication should be given to untreated hypertensives (CCBs or RAASi); (ii) could such medications mitigate the risk; and (iii) will RAASi affect risk of infection when equally exposed to the virus?</td>
   </tr>
   <tr>
    <td>5. Gnavi R, et al. doi: 10.1093/cid/ciaa634.</td>
    <td>Association between RAASi and COVID-19 in hypertensives (HY) and patients with circulatory diseases/diabetes (CDD).</td>
    <td>316 HY and 171 CDD cases of COVID-19 infection matched with 1580 and 855 controls.</td>
    <td>No reason to modify antihypertensive therapy. Study limited to explore whether RAAS therapy increases the risk of SARS-CoV-2 infection</td>
    <td>Small sample size</td>
   </tr>
   <tr>
    <td>6. Guo T, et al. doi: 10.1001/jamacardio.2020.1017.</td>
    <td>Association of underlying CVD and myocardial injury with fatal outcomes in COVID-19.</td>
    <td>187 patients with COVID-19.</td>
    <td>Myocardial injury associated with fatal outcome of COVID-19. Prognosis of patients with CVD but without myocardial injury relatively favorable.</td>
    <td>
     <p>Small sample size</p>
     <p>Significantly increased TnT levels in patients with ACEi/ARB use history.</p>
    </td>
   </tr>
   <tr>
    <td>7. Jung S-Y, et al. doi: 10.1093/cid/ciaa624/5842160.</td>
    <td>Associations between prior use of RAASi and clinical outcomes among Korean patients with COVID-19.</td>
    <td>5179 COVID-19 cases.</td>
    <td>Prior use of RAASi not independently associated with mortality in COVID-19. Controversy regarding the role of RAAS blockade in COVID-19 calls for urgent multicenter trials.</td>
    <td>Unadjusted in-hospital mortality for 33 RAASi users 9% and 51 nonusers 3% (
     <italic>p</italic> &lt; 0.001).
    </td>
   </tr>
   <tr>
    <td>8. Li J, Wang X, et al. doi: 10.1001/jamacardio.2020.1624.</td>
    <td>Investigation of whether hypertensives taking ACEi/ARB have increased severity of illness or risk of mortality during hospitalization for COVID-19.</td>
    <td>1178 hospitalized patients with COVID-19.</td>
    <td>ACEi/ARB not associated with the severity or mortality of COVID-19 in hospitalized hypertensive patients.</td>
    <td>Small number of patients taking ACEIs/ARBs. Uncertain whether the ACEi/ARB treatment was maintained throughout hospitalization.</td>
   </tr>
   <tr>
    <td>9. Mancia G, et al. Renin–Angiotensin: 10.1056/NEJMoa2006923.</td>
    <td>Association between the use of ARBs/ACEi and risk of COVID-19.</td>
    <td>6272 patients COVID-19 patients matched to 30,759 controls.</td>
    <td>More frequent use of ACEi/ARB in patients with COVID-19 than controls attributed to higher prevalence of cardiovascular disease. ACEi/ARB did not affect the risk of COVID-19.</td>
    <td>Information on drug use limited to prescriptions, and actual drug consumption by the case patients and controls was not assessed.</td>
   </tr>
   <tr>
    <td>10. Mehra MR, et al. doi: 10.1056/NEJMoa2007621.</td>
    <td>-</td>
    <td>-</td>
    <td>-</td>
    <td>Retracted doi: 10.1056/NEJMc2021225.</td>
   </tr>
   <tr>
    <td>11. Mehta N, et al. doi: 10.1001/jamacardio.2020.1855.</td>
    <td>Role of ACEi and ARB in the setting of COVID- 19.</td>
    <td>18,472 patients tested for COVID-19.</td>
    <td>No association between ACEi or ARB use and COVID-19 test positivity. Further study in larger numbers of hospitalized patients receiving ACEi-ARB therapy is needed.</td>
    <td>Among patients with positive test and overlap propensity score weighing, 54% taking ACEi (vs 39% not taking ACEi) were admitted to hospital; 24% taking ACEi (vs 15% not taking ACEIs) were admitted to ICU; and 14% taking ACEi (vs 11% not taking ACEi) required mechanical ventilation. Similarly, 53% taking ARB (vs 41% not taking ARB) were admitted to hospital; 20% taking ARB (vs 18% not taking ARB) were admitted to ICU; and 14% taking ARB (vs 12% not taking ARB) required mechanical ventilation.</td>
   </tr>
   <tr>
    <td>12. Meng, J, et al. doi: 10.1080/22221751.2020.1746200.</td>
    <td>Association between ACEi/ARB and clinical outcomes in COVID-19 patients with hypertension.</td>
    <td>417 hospitalized patients with COVID-19.</td>
    <td>ACEi/ARB improve clinical outcomes of COVID-19 patients with hypertension.</td>
    <td>Small sample size</td>
   </tr>
   <tr>
    <td>13. Rentsch CT, et al. doi: 10.1101/2020.04.09.20059964.</td>
    <td>Association between demographic and clinical characteristics and testing positive for COVID-19, and among COVID-19+ subsequent hospitalization and intensive care.</td>
    <td>2,026,227 Veterans aged 54–75 years and active in care, 585/3789 (15.4%) tested COVID-19+.</td>
    <td>Racial differences in testing positive for COVID-19 underestimate of general population. Risk of hospitalization and intensive care better characterized by laboratory measures and vital signs.</td>
    <td>
     <p>Preprint</p>
     <p>History of ACEi/ARB use associated with increased risk of ICU admission.</p>
    </td>
   </tr>
   <tr>
    <td>14. Reynolds HR, et al. doi: 10.1056/NEJMoa2008975.</td>
    <td>Association between treatment with ACEi, ARB, BBs, CCBs, or thiazides and likelihood of a) positive or negative COVID-19 testing, and b) severe illness among patients who tested positive.</td>
    <td>12,594 patients tested for Covid-19 [(46.8%) positive; 1002 (17.0%) severe illness].</td>
    <td>Νo substantial increase in likelihood of a positive COVID-19 test or risk of severe COVID-19 among patients who tested positive in association with antihypertensive medications.</td>
    <td>Possible overestimation of the proportion of cases with severe COVID-19. The electronic health records used may not reflect actual drug exposure.</td>
   </tr>
   <tr>
    <td>15. Richardson S, et al. doi: 10.1001/jama.2020.6775.</td>
    <td>Clinical characteristics and outcomes of hospitalized patients with COVID-19.</td>
    <td>Case series of patients (
     <italic>n</italic> = 5700) with COVID-19 admitted to hospital.
    </td>
    <td>This study provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19.</td>
    <td>Unadjusted mortality rates for hypertensives not taking an ACEi/ARB, taking an ACEi, and taking an ARB were 26.7%, 32.7%, and 30.6%, respectively.</td>
   </tr>
   <tr>
    <td>16. Rossi PG, et al. doi: 10.1101/2020.04.13.20063545.</td>
    <td>Age- and sex-specific prevalence of COVID-19 and its prognostic factors.</td>
    <td>2653 symptomatic patients who tested positive for SARS-CoV.</td>
    <td>Deeper understanding of causal chain from infection, disease onset, and immune response to outcomes.</td>
    <td>
     <p>Preprint</p>
     <p>Association between ACEi and hospitalization, likely due to residual confounding.</p>
    </td>
   </tr>
   <tr>
    <td>17. Tedeschi S, et al. doi: 10.1093/cid/ciaa492.</td>
    <td>Investigation of whether treatment with RASi, has an impact on in-hospital mortality in hypertensives hospitalized for COVID-19.</td>
    <td>311 hypertensives hospitalized for COVID-19.</td>
    <td>Use of RASi not associated with outcome.</td>
    <td>
     <p>Letter to the editor</p>
     <p>Small sample size</p>
    </td>
   </tr>
   <tr>
    <td>18. Yang G, et al. doi: 10.1101/2020.03.31.20038935.</td>
    <td>Correlation of ARB/ACEi usage with the pathogenesis of COVID-19.</td>
    <td>126 hypertensive COVID-19 patients.</td>
    <td>Findings support use of ARB/ACEi in hypertensive COVID-19 patients.</td>
    <td>
     <p>Preprint</p>
     <p>Small sample size</p>
    </td>
   </tr>
   <tr>
    <td>19. Zeng Z, et al. doi: 10.1101/2020.04.06.20054825</td>
    <td>
     <p>Investigation of whether hypertensives are more likely to be infected with SARS-COV-2 than the general population and whether there is a difference in severity of</p>
     <p>COVID-19 pneumonia in patients who have taken ACEi/ARB.</p>
    </td>
    <td>274 hospitalized hypertensives with clinically confirmed COVID-19.</td>
    <td>Hypertensives with COVID-19 who had taken ACEi/ARB drugs at increased risk to develop severe pneumonia.</td>
    <td>
     <p>Preprint</p>
     <p>Small sample size</p>
    </td>
   </tr>
   <tr>
    <td>20. Zhang P, et al. doi: 10.1161/CIRCRESAHA.120.317134.</td>
    <td>Association between in-hospital use of ACEi/ARB and all-cause mortality in hypertensive COVID-19 patients.</td>
    <td>1128 hospitalized hypertensives with COVID-19.</td>
    <td>Unlikely that in-hospital use of ACEi/ARB was associated with an increased mortality risk. Potential for residual confounders not considered.</td>
    <td>Traditional Chinese medicine given in 91% of ACEi/ARB group and 86% of non-ACEi/ARB group.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>ACEi</italic> angiotensin-converting enzyme inhibitor, 
   <italic>ARB</italic> angiotensin receptor blocker, 
   <italic>BBs</italic> beta-blockers, 
   <italic>RAASi</italic> renin angiotensin aldosterone system inhibitors, 
   <italic>RASi</italic> renin angiotensin system inhibitors, 
   <italic>CCBs</italic> calcium channel blockers, 
   <italic>CVD</italic> cardiovascular disease, 
   <italic>TnT</italic> troponin T
  </p>
 </table-wrap-foot>
</table-wrap>
